Europe Alopecia Areata Market
Europe alopecia areata market is expected to reach USD 4,633.68 million by 2031 from USD 2,591.02 million in 2023, growing with a CAGR of 7.5% in the forecast period of 2024 to 2031.
Market Segmentation:
Europe Alopecia Areata Market, By Disease Type (Alopecia Areata (Patchy), Alopecia Areata Totalis, Alopecia Areata Universalis, and Others), Cause (Non-Genetic and Genetic), Type (Treatment and Diagnosis), Age Group (Below 18 Years, 18-50 Years, and Above 50 Years), Gender (Female and Male), Country (Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and rest of Europe) - Industry Trends and Forecast to 2031
Overview of Europe Alopecia Areata Market Dynamics:
Driver
• Increase in geriatric population
Restraint
• Side effects associated with the available hair loss treatment therapies
Opportunity
• Development and technological advancements in hair treatment medical devices
Market Players:
The key market players operating in the Europe alopecia areata market are listed below:
• Pfizer Inc.
• Dr. Reddy's Laboratories Ltd.
• Lilly
• Sun Pharmaceutical Industries Ltd.
• GSK plc.
• Johnson & Johnson Consumer Inc.
• Lupin
• Croma-Pharma GmbH
• Viviscal Limited (A Subsidiary of Church & Dwight Co.)
• Wellona Pharma
• Teva Pharmaceuticals USA, Inc.
• Croma-Pharma GmbH
• Follicum AB
• Nanogen
• Vitabiotics Ltd.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. This publisher does offer titles that are created upon receipt of order.